Original ArticleReduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study
Under a Creative Commons license
open archive
KEYWORDS
alloantibody
calcineurin inhibitor: tacrolimus
clinical research/practice
glomerular filtration rate (GFR)
immunosuppressant
immunosuppression/immune modulation
immunosuppressive regimens
kidney transplantation/nephrology
maintenance
rejection
Abbreviations
aah
arteriolar hyaline thickening
ABMR
antibody-mediated rejection
BPAR
biopsy-proven acute rejection
BR
before randomization
C0
trough level
cg
glomerular double contours
ci
interstitial fibrosis
CMV
cytomegalovirus
CNI
calcineurin inhibitor
ct
tubular atrophy
cv
fibrous intimal thickening
DGF
delayed graft function
DSA
donor-specific antibody
EC-MPS
enteric-coated mycophenolate sodium
eGFR
estimated GFR
ESRD
end-stage renal disease
g
glomerulitis
HbA1c
glycosylated hemoglobin
HDL
high-density lipoprotein
LDL
low-density lipoprotein
i
inflammation
IF/TA
interstitial fibrosis/tubular atrophy
KTR
kidney transplant recipient
M
month
MMF
mycophenolate mofetil
mTOR
mammalian target of rapamycin
NS
not significant
PR
just after randomization
ptc
peritubular capillaritis
PTDM
posttransplant diabetes mellitus
t
tubulitis
TacER
extended-release tacrolimus
TCMR
T cell–mediated rejection
v
intimal arteritis
Cited by (0)
Copyright © 2017 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.